Sep. 22 at 11:06 AM
$NVO is getting more interesting as the story shifts from simply defending Wegovy to building the next obesity growth engine.
Novo has signaled it is open to larger M&A, while the recent Orbis partnership shows it is looking beyond traditional GLP-1s into oral cardiometabolic technology.
Fundamentals are also improving: 2026 adjusted sales/operating-profit guidance has been raised twice, now to 0% to -6%.
The key risk remains lower realized pricing as competition with
$LLY intensifies.
Technical watch: I’m watching
$37.80–
$42.03 as an interesting area. Worst-case risk sits near
$35.22, while a recovery could target around
$50.78.
The real catalyst: whether Novo can use M&A to build what comes after Wegovy.
